Literature DB >> 7690885

Induction and removal of interstrand crosslinks in the ribosomal RNA genes of lymphoblastoid cell lines from patients with Fanconi anemia.

J P Rey1, R Scott, H Müller.   

Abstract

The repair of interstrand crosslinks has been investigated in Fanconi anemia (FA) and normal cells as there is evidence suggesting that FA patients have a defect in DNA repair. Lymphoblasts were treated with the crosslinking agent mitomycin C (MMC) and the removal of the induced DNA lesions investigated at the level of the actively transcribed ribosomal RNA (rRNA) genes. MMC-induced crosslinks appeared to be a rather stable lesion in the rRNA genes for all cell lines studied. Variable repair efficiencies were found between the different cells lines but they could not be used to distinguish normal cells from FA cells. Therefore, we propose that the specific sensitivity of FA cells towards MMC cannot be directly correlated with a deficient repair in interstrand crosslinks and that probably the complexity of the repair process is greater than previously described.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690885     DOI: 10.1016/0027-5107(93)90067-p

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  3 in total

1.  FANCD2 monoubiquitination and activation by hexavalent chromium [Cr(VI)] exposure: activation is not required for repair of Cr(VI)-induced DSBs.

Authors:  Susan K Vilcheck; Susan Ceryak; Travis J O'Brien; Steven R Patierno
Journal:  Mutat Res       Date:  2006-08-08       Impact factor: 2.433

2.  Cytoplasmic localization of FAC is essential for the correction of a prerepair defect in Fanconi anemia group C cells.

Authors:  H Youssoufian
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

Review 3.  The cell's nucleolus: an emerging target for chemotherapeutic intervention.

Authors:  Amanda J Pickard; Ulrich Bierbach
Journal:  ChemMedChem       Date:  2013-07-23       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.